Long-term efficacy and safety of brigatinib in crizotinib-refractory alk+ nsclc: final results of the phase 1/2 and randomized phase 2 (alta) trials

HIGHLIGHTS

• who: Scott N. Gettinger MD from the Thoracic Centre Munich, University Hospital of Munich, member of the German Center for Lung Research (DZL, CPC-M), Munich, Germany have published the article: Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials, in the Journal: (JOURNAL) of September/20,/2011
• what: The authors report brigatinib long-term efficacy and safety from phase 1/2 and phase 2 (ALTA) trials in ALK- rearrangement positive (ALK-) NSCLC. The authors report long-term outcomes . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.